Chronic sulforaphane application does not induce resistance in renal cell carcinoma cells

8Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Since the natural compound sulforaphane (SFN) has been shown to stop tumor growth, renal cell carcinoma (RCC) patients often use this drug in addition to their prescribed oncotherapy. The aim of this study was to examine whether resistance to SFN may develop after long-term application. Materials and Methods: Several RCC cell lines were incubated with SFN for short periods of time (24-72 h) or long periods of time (8 weeks) and cell growth, proliferation, and cell-cycle proteins were analyzed. Results: Both short- and long-term application of SFN distinctly reduced RCC cell growth and proliferation. However, differences in the distribution of cells in each phase of the cell cycle and in the expression of cell-cycle proteins were apparent. Short-term treatment induced Sphase arrest, whereas long-term treatment induced G0/G1- phase arrest. Expression of Cdk1 and Cdk2 increased over short-term incubation, but decreased long-term. Expression of pCdk2, Akt, and Raptor were reduced following long-term SFN-exposure, but remained unchanged when SFN was applied for short periods of time. Conclusion: Chronic use of SFN did not evoke resistance, but differentially altered signaling pathways, compared to short-term use.

Cite

CITATION STYLE

APA

Rutz, J., Juengel, E., Euler, S., Maxeiner, S., Justin, S., Roos, F., … Blaheta, R. A. (2018). Chronic sulforaphane application does not induce resistance in renal cell carcinoma cells. Anticancer Research, 38(11), 6201–6207. https://doi.org/10.21873/anticanres.12974

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free